PMID- 35695096
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20221121
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 63
IP  - 10
DP  - 2022 Oct
TI  - Whole-genome sequencing as an alternative to analyze copy number abnormalities in 
      acute myeloid leukemia and myelodysplastic syndrome.
PG  - 2301-2310
LID - 10.1080/10428194.2022.2080821 [doi]
AB  - Copy number aberrations (CNA) are the core determinants for diagnosis, risk 
      stratification and prognosis in acute myeloid leukemia (AML) and myelodysplastic 
      syndrome (MDS). In this study, a shallow whole-genome sequencing-based assay, 
      LeukoPrint, was utilized to depict genomic CNA profiles from the bone marrow of 
      137 newly diagnosed AML/MDS patients. It demonstrated 98.1% concordance of CNA 
      profiles with cytogenetics and/or fluorescence in situ hybridization (FISH). It 
      is advantageous in detecting CNAs of short segments (1 Mb) and from samples with 
      low leukemic cell content, more accurate for describing complex karyotypes and 
      less confounded by subjective bias. LeukoPrint improved the overall diagnostic 
      yield by redefining the risk categories for 16 patients by presenting new 
      information. In summary, LeukoPrint provided an automated, convenient, and 
      cost-effective approach to describe genomic CNA profiles. It brought greater 
      diagnostic yield and risk stratification information by incorporating into the 
      routine cytogenetics based on the CNA-related criteria of standard ELN/IPSS-R 
      guidelines.
FAU - Lyu, Xiaodong
AU  - Lyu X
AUID- ORCID: 0000-0002-0155-5927
AD  - Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University and 
      Henan Cancer Hospital, Zhengzhou, China.
FAU - Li, Tao
AU  - Li T
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhu, Dandan
AU  - Zhu D
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Cheng, Yuexin
AU  - Cheng Y
AD  - Department of Hematology, Yancheng No. 1 People's Hospital, Yancheng, China.
AD  - Department of Hematology, The Yancheng Clinical College of Xuzhou Medical 
      University, Yancheng, China.
FAU - Chen, Yan
AU  - Chen Y
AD  - Research & Development, SeekIn Inc., Shenzhen, China.
FAU - He, Xiangxiang
AU  - He X
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Li, Zhenling
AU  - Li Z
AD  - Department of Hematology, China-Japan Friendship Hospital, Beijing, China.
FAU - Li, Shiyong
AU  - Li S
AUID- ORCID: 0000-0003-0416-526X
AD  - Research & Development, SeekIn Inc., Shenzhen, China.
FAU - Wu, Wei
AU  - Wu W
AD  - Research & Development, SeekIn Inc., Shenzhen, China.
FAU - Geng, Shuaipeng
AU  - Geng S
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Zhang, Mengna
AU  - Zhang M
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Yao, Chunxiao
AU  - Yao C
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Li, Jingshuai
AU  - Li J
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Li, Yangwei
AU  - Li Y
AD  - Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University and 
      Henan Cancer Hospital, Zhengzhou, China.
FAU - Chang, Yinyin
AU  - Chang Y
AD  - Clinical Laboratories, Shenyou Bio, Zhengzhou, China.
FAU - Li, Yuchun
AU  - Li Y
AD  - Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University and 
      Henan Cancer Hospital, Zhengzhou, China.
FAU - Zhu, Zunmin
AU  - Zhu Z
AUID- ORCID: 0000-0002-6635-7454
AD  - Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China.
FAU - Mao, Mao
AU  - Mao M
AUID- ORCID: 0000-0002-8570-8571
AD  - Research & Development, SeekIn Inc., Shenzhen, China.
AD  - Yonsei Song-Dang Institute for Cancer Research, Yonsei University, Seoul, Korea.
FAU - Song, Yongping
AU  - Song Y
AD  - Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University and 
      Henan Cancer Hospital, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220611
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Abnormal Karyotype
MH  - Chromosome Aberrations
MH  - DNA Copy Number Variations
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Leukemia, Myeloid, Acute/diagnosis/genetics
MH  - *Myelodysplastic Syndromes/diagnosis/genetics
OTO - NOTNLM
OT  - Copy number aberrations
OT  - myeloid neoplasms
OT  - sWGS
EDAT- 2022/06/14 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/06/13 05:53
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/06/13 05:53 [entrez]
AID - 10.1080/10428194.2022.2080821 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2022 Oct;63(10):2301-2310. doi: 10.1080/10428194.2022.2080821. 
      Epub 2022 Jun 11.